

Obiltoxaximab SFL (*obiltoxaximabum*)

D Y_A Y_X d_{fc} d_{dfUj} Y_{_CV}]hcl UI]a UV G: @U d_{fc} Vm d_{dfUj} Y_{_fY}]ghfcj z b v EU

7c. d_{dfUj} Y_{_CV}]hcl UI]a UV G: @U_ Ya i gY dci yj z 3

D_{dfUj} Y_{_CV}]hcl UI]a UV G: @Y f j d_{dfUj} Y_{_dci} yj Ub j Kombinaci s f Vci 'Ubh[V]ch]_m_`f V d]Wb c'UbhfUI i zWt y'Y nzj Uyb f'cbYa cW bfnnd gcVYbf'VU_hYf]Bacillus anthracis"PD]Wb nbUa Ybz z yY XUbz cgcVU gY hta hc'cbYa cW bta bU_Untj XYVcj zbt gdcfz'nY_hYf W gY j h 'Y j nj]bci 'U_hj b f VU_hYf]Y'U'bzg'YXb i j c i y_cX]j f hcl]bm

HYbhc f j d_{dfUj} Y_{_gY_dci} yj z 'HU_f_ dfYj YbW d]WAc'UbhfUI i i cgcVz_hYff gY'XcgHUmXc'cbHJ_h s h a]h'VU_hYf]z bta]gdcfUa]z'U j d_{dfU}XYWz_XmyzXbz 'jbz j \cXbz 'f VU'bYb f_X]gdcn]W

D_{dfUj} Y_{_CV}]hcl UI]a UV G: @cVgU i Y f j ci zh_i 'cV]hcl UI]a UV

5bhfUI 'Y j nzWb f'cbYa cW b fU d_{dfUj} Y_{_CV}]hcl UI]a UV G: @Vm cnbU Yb'XbY &("gfdbU'&\$% 'U_c' Pf j d_{dfUj} Y_{_dfc} j nzWb z'cbYa cW b f "8U'yf]bZfa UW c'ha hc'j nzWb fa'cbYa cW b f bU'YnbYhY nXY. ema.europa.eu/medicines/human/orphan-designations/eu3182065.

>U_ gY d_{dfUj} Y_{_CV}]hcl UI]a UV G: @dci yj z 3

J XY^d_{dfUj} _i 'CV]hcl UI]a UV G: @Y j znb bU f_U g_ d YXd]g" D_{dfUj} Y_{_Vma} "V hdcXzj z b' v a tgh z_XY'Y a c ybf fmW Y fYU[cj Uh'bU nzj Uyb f'U'Yf]]W f'fYU_W"

D_{dfUj} Y_{_CV}]hcl UI]a UV G: @gY dcXzj z Zfa ci 'YXbcfz ncj f]bZ nY f'Udz bXc' y f'mdc'XcVi - \$'a]bi h' Doporu Ybz'Xzj 'U'nzj]g f bU'h 'Ygbf' a chbcgh'dUWbHJ'D YX dcXzbta d_{dfUj} _i 'CV]hcl UI]a UV G: @Y a c ybf'dUWbH a' dcXUh'f j f d_{dfUj} _m_ dfYj YbW U'Yf]]W_ W f'fYU_W bYVc'Y jW ca YnYb f'

J W]bZfa UW c'dci yj z b f d_{dfUj} _i 'CV]hcl UI]a UV G: @bU'YnbYhY j d f'U'c j f]bZfa UW bYVc'gY' cVfU hY' bU'gj f'c f_U Y']'f_zfb f U"

>U_ d_{dfUj} Y_{_CV}]hcl UI]a UV G: @d_ gcVf3

Nzj Uyb f'•]b_m'UbhfUI i 'gci nd gcVYbmhcl]bYa z_hYf'VU_hYf]Y'nd gcVi 'W'UbhfUI 'dfcXi _i y' CV]hcl UI]a UV 'Y a cbc'cbz' b f dfch'z_h_Uz_Wt y'Y hm'd'Vf_cj]bmz_hYfz'VmU'j nj]bi hU'U_ z'UVmgY' bUj znU'U' bU'g'c y_i 'hcl]bi 'UbhfUI i 'nj Ubc i 'PdfchY_hj b f'Ubhj]Yb'UbhfUI i 'z_hYfz i a c y i 'Y j ghi d' hcl]bi 'Xc'Vi b _"

D YXdc_`zXz `gYž`yY bUj znzbža `gY`bU`dfchY_hj b‡Ubhj[Yb `Ubhfu i `f]j c `nUvfu i `Y`j ghi di `hcl]bi `Xc` Vi b _`h `Už` ža žna ‡f i `Y`d ‡nbU_mbYVc `ja `d YXWznf

>U_f d ‡bcgm̄d ‡dfUj _i `CV]hcl UI ja UV G: @Vm̄midfc_znzbm̄j df V \i `gh X]‡3

BU`nz_`UX `gh X]‡bU`nj ‡UhYw `Y`d ‡dfUj Y_`CV]hcl UI ja UV G: @dcj Ujcy z b`j fza W`f Vmid]WbAc` Ubhfu i `nU` .]bb "J fza W`f `gh X]‡i `]bz_cj Ub W`nj ‡Uhig d ‡nbU_migY`a ‡fm̄d Yy]hdc\mVcj U`m v fcna Ynfd Jy]b `cC` \$ do 60 i `i`d ‡dfUj _i `CV]hcl UI ja UV G: @j Y`gfcj bzb‡g \$ `Uy`* % u placebo fbY`]bbf\c`d ‡dfUj _i `t`J Y`gh X]‡j Y`_hYff`Vm`]bz_cj Ub a `nj ‡Uh a `dcXzj z b`f]j `d ‡dfUj Y_`bYVc` pIUVVc`Yy` d YX`hža žbYy`gY`dfc`Yj`]md ‡nbU_mž`gY`a ‡fU`d Yy]hdc\mVcj U`U`cX` \$ do 100 i `d`]i yž z b‡d ‡dfUj _i `CV]hcl UI ja UV G: @j nzj]g`cgh`bU`hca žnU`U`X`ci \c`dc`bU`UyYp`VmU`i `nj ‡Uh nU`z`YbU`f VUž`d] Ya yžnY`nj ‡Uhž`hYf a `Vm`dcXzj z b`d`UVVcž`bYd Yy]c`yžXbf

>U_z `f]n_U`gci `gdc`YbU`g d ‡dfUj _Ya `CV]hcl UI ja UV G: @3

BY^ Ugh yža]bYyžXci W`a]`]b_m̄d ‡dfUj _i `CV]hcl UI ja UV G: @fL_hYfj a c\ci `dcgh\`bci h`Uy`%`cgcVi` n`\$L`gci `Vc`Ygh`Uj mž`dfi f]h`g`f`j` X`b#z_c`d`]j`_U`f`j` X`j`z`j`nfzy_Už`j`nfzy_Už`_Uyel, bolest v a tg` Ud`]UW`]bz_nY`U`dcW`]h`nj`fU`h`

i d`b `gYnbUa `bYyžXci W`W` .]b_`U`ca YnYb‡d ‡dfUj _i `CV]hcl UI ja UV G: @Y`i`j`YXYb`j` d `U`c`j`f` informaci.

BU`nz_`UX `Y\c`Vm`d ‡dfUj Y_`CV]hcl UI ja UV G: @fY[]ghfcj z b`j` 91`3

D`Wb‡Ubhfu `Y`y`j`ch`c\fc`y` `M`cbYa cWb`b#z_hYff`j`50`i`d`‡dUX`j`YXY`_`a`fht`=_Xmy`gY`d`]fcnYbz` j`nd`Ubi`h`bz`_Unmj`mg`_m̄i`y`j`Y`a`]`n`X`Už`a`y`Y`bYy`Ugh`bci`bz\cXci`Xc`h`_j`g`_m̄i`]bzY_W` v`UvcfUh`‡W`_hYff`hmc`VU`hYf`Y`n`ci`a`y`Y`V`hdc`y`h`d`]hYfcf]gh]W`W`*`h`W`W` Jnhledem k`h`a`i`ž`y`dc`Yh`d`‡dUX`Y`H`U`b`h`_U`_`a`m`b`f`]bz_cj`z`b‡cgcV`Y`d`‡`j`y`b`Y`V`nd`Y`b`f`ž`b`Y`b`‡`a`c`y`b`f`dfc`j`f`gh`gh`X`Y`h`c\ch`_f`]j`f\c`d`‡dfUj`_i`i`_`X`f`G`h`X`Y`b`U`nj`‡UhYw`dfc`_znU`mž`y`Y`h`b`h`c`_f`]j` d`‡dfUj`Y_`Y` .]bb`j`_f`V`Ubhfu i`U`dfYj`YbW`·`a`fht`U`d`YXdc_`zXz`gYž`y`d`‡dfUj`Y_`CV]hcl UI ja UV G: @Vi`XY`i`_`]X`‡`d`g`c`V`h`gh`Y`b`a`nd`g`c`V`ya`"`N`Y`X`j`g`U`V`Y`nd`Y`bcg`h`gci`b`YyžXci`W`·`]b_m̄d`‡dfUj`_i`CV]hcl UI ja UV G: @i`nXfUj`W`_`]X`‡`c`V`j`m`_Y`a`f`b`f`U`y`gh`Y`X`b`nj`U`y`b`f`"5`[`Y`b`h`f`U`dfc`h`fcn\cX`Už`y`Y` d`bcgm̄d`‡dfUj`_i`CV]hcl UI ja UV G: @d`Y`j`m`y`‡`Y`c`f]n`Už`U`a`y`Y`H`U`_V`h`f`Y[]ghfcj`z`b`_`d`c`i`y`h`f`j`EU.

D`‡dfUj`Y_`CV]hcl UI ja UV G: @Vm`fY[]ghfcj`z`b`nU`_`j`ja`Y`b`W`c`c`bcg`h`ž`b`Y`Vc`j`n`Y`Y`xa`_Y`j`nz`W`f` dcj`UnY`h`c\ch`cb`Ya`cWb`b`f`U`h`Y`j`W`W`X`j`c`X`b`Y`V`m`a`c`y`b`f`c`d`‡dfUj`_i`CV]hcl UI ja UV G: @n`g`_U`h`·`d`b`f`]bz`fa`UW`"5`[`Y`b`h`f`U`U`y`X`c`f`U`_f`c`]`bc`j`f`]bz`fa`UW`U`h`b`h`c`d`Y`Y`X`Vi`XY`dc`X`Y` d`Y`X`c`y`Y`b`m`·`X`U`Y`c`·`]bb`c`gh`U`V`Y`nd`Y`bcg`h`f`]j`f\c`d`‡dfUj`_i`d`]a`c`y`b`fa`df`cd`_bi`h`‡Ubhfu`i`"

>U_f `]bz`fa`UW`c`d`‡dfUj`_i`CV]hcl UI ja UV G: @b`Y`Vm`m`X`c`gi`X`d`Y`X`c`y`Y`b`m`3

>Y`_c`y`d`‡dfUj`Y_`CV]hcl UI ja UV G: @Vm`fY[]ghfcj`z`b`nU`j`_ja`Y`b`W`c`c`bcg`h`ž`gdc`Y`bcg`h`ž`hYf`z` d`‡dfUj`Y_`CV]hcl UI ja UV G: @XcXzj`z`b`U`h`f`_d`Y`X`c`y`f`X`U`y`·`X`U`Y`c`a`Y`h`c`X`z`W`a`Y`b`f`h`c\c`z`U`_`Y` d`‡dfUj`Y_`j`_U`v`c`f`U`h`c`fb`‡W`g`h`X`j`gh`Y`V`z`j`bz`a`c`X`z_cj`z`b`U`c`X`g`f`U`c`j`z`b`n`h`U`U`B`U`j`W`m`a`_m`V`h` d`Y`X`c`y`Y`b`m`·`X`U`Y`c`·`]bb`c`gh`U`V`Y`nd`Y`bcg`h`f`]j`f\c`d`‡dfUj`_i`d`]a`c`y`b`fa`df`cd`_bi`h`‡Ubhfu`i`"

>U_z `cd`U`h`Y`b`‡`g`ci`i`d`U`h`c`j`z`b`U`_n`U`y`h`b`‡`V`Y`nd`Y`b`f`c`U`·`]bb`f`c`·`d`c`i`y`j`z`b`‡`d`‡dfUj`_i`CV]hcl UI ja UV G: @3

8c`gci`f`b`i`·`X`U`^`c`d`‡dfUj`_i`U`d`U`c`j`f`]bz`fa`UW`V`m`U`n`U`f`b`i`h`X`c`d`f`i`Y`b`‡`U`cd`U`h`Y`b`‡`f`c`V`Y`nd`Y`b`f` U`·`]bb`f`d`c`i`y`j`z`b`‡`d`‡dfUj`_i`CV]hcl UI ja UV G: @`_hYf`z`V`m`a`_U`V`h`X`c`X`f`y`c`j`z`b`U`n`X`f`U`j`c`h`]W`a`]` df`U`W`j`b`t`m`]d`U`W`Y`b`m`

šU_c'i'j yYVW'f jj W'd #fUj _ 'gci '• XU'Y'c'dci y‡ zbf d #fUj _i 'CV]hcl Ul]a UV'G: @df V yb
g'YXcj z bm' BYyzXci W•]b_mbUV'z yYbf'j souvislosti s d #fUj _Ya 'CV]hcl Ul]a UV'G: @'gci 'dY 'jj
\cXbcWbmU'gci 'i]b bU'j Yy_Yfz 'bYnVnfbz 'cdUh Yb‡'UVmVm'c Wfzb bc 'nXfUj #dUWYbh "

8U'ý‡]bZcfa UW'c'd #fUj _i 'CV]hcl Ul]a UV'G: @

8U'ý‡]bZcfa UW'c'd #fUj _i 'CV]hcl Ul]a UV'G: @'gcu k X]gdcn]W'bU']bhYfbYhcj W'ghfzb_zW'U[Ybh fmbU'
adrese ema.europa.eu/medicines/human/EPAR/Obiltoxaximab-SFL.

P€·pavek ji, nen. registrovfn